The association of higher levels of within-normal-limits liver enzymes and the prevalence of the metabolic syndrome

Cardiovascular Diabetology

Volumn 9, Issue , 2010, Pages

  Steinvil, Arie ^a   Shapira, Itzhak ^a   Ben Bassat, Orit K ^a   Cohen, Michael ^a   Vered, Yaffa ^b   Berliner, Shlomo ^a   Rogowski, Ori ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE;

ADULT; ARTICLE; FEMALE; HUMAN; MALE; METABOLIC SYNDROME X; NORMAL HUMAN; PREVALENCE; BLOOD; CROSS-SECTIONAL STUDY; ENZYMOLOGY; ISRAEL; LIVER; METABOLISM; MIDDLE AGED;

ADULT; ALANINE TRANSAMINASE; CROSS-SECTIONAL STUDIES; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; ISRAEL; LIVER; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE;

EID: 77954843547     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-9-30     Document Type: Article

References (42)

1. Dekker JM, Girman C, Rhodes T, Nijpels G, Stehouwer CD, Bouter LM, Heine RJ. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 2005, 112:666-673. 10.1161/CIRCULATIONAHA.104.516948, 16061755.
2. Jeppesen J, Hansen TW, Rasmussen S, Ibsen H, Torp-Pedersen C, Madsbad S. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study. J Am Coll Cardiol 2007, 49:2112-2119. 10.1016/j.jacc.2007.01.088, 17531661.
3. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. Jama 2002, 288:2709-2716. 10.1001/jama.288.21.2709, 12460094.
4. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, Williams GR. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004, 110:1245-1250. 10.1161/01.CIR.0000140677.20606.0E, 15326067.
5. Devers MC, Campbell S, Shaw J, Zimmet P, Simmons D. Should liver function tests be included in definitions of metabolic syndrome? Evidence from the association between liver function tests, components of metabolic syndrome and prevalent cardiovascular disease. Diabet Med 2008, 25:523-529. 10.1111/j.1464-5491.2008.02408.x, 18346165.
6. Andre P, Balkau B, Vol S, Charles MA, Eschwege E. Gamma-glutamyltransferase activity and development of the metabolic syndrome (International Diabetes Federation Definition) in middle-aged men and women: Data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR) cohort. Diabetes Care 2007, 30:2355-2361. 10.2337/dc07-0440, 17586745.
7. Nannipieri M, Gonzales C, Baldi S, Posadas R, Williams K, Haffner SM, Stern MP, Ferrannini E. Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes Care 2005, 28:1757-1762. 10.2337/diacare.28.7.1757, 15983331.
8. Hanley AJ, Williams K, Festa A, Wagenknecht LE, D'Agostino RB, Haffner SM. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes 2005, 54:3140-3147. 10.2337/diabetes.54.11.3140, 16249437.
9. Liangpunsakul S, Chalasani N. Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III). Am J Med Sci 2005, 329:111-116. 10.1097/00000441-200503000-00001, 15767815.
10. Goessling W, Massaro JM, Vasan RS, D'Agostino RB, Ellison RC, Fox CS. Aminotransferase Levels and 20-Year Risk of Metabolic Syndrome, Diabetes, and Cardiovascular Disease. Gastroenterology 2008, 135(6):1935-44. 1944.e, 10.1053/j.gastro.2008.09.018, 19010326.
11. Emdin M, Passino C, Michelassi C, Titta F, L'Abbate A, Donato L, Pompella A, Paolicchi A. Prognostic value of serum gamma-glutamyl transferase activity after myocardial infarction. Eur Heart J 2001, 22:1802-1807. 10.1053/euhj.2001.2807, 11549302.
12. Jousilahti P, Rastenyte D, Tuomilehto J. Serum gamma-glutamyl transferase, self-reported alcohol drinking, and the risk of stroke. Stroke 2000, 31:1851-1855.
13. Lee DH, Silventoinen K, Hu G, Jacobs DR, Jousilahti P, Sundvall J, Tuomilehto J. Serum gamma-glutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28,838 middle-aged men and women. Eur Heart J 2006, 27:2170-2176. 10.1093/eurheartj/ehl086, 16772340.
14. Lee DS, Evans JC, Robins SJ, Wilson PW, Albano I, Fox CS, Wang TJ, Benjamin EJ, D'Agostino RB, Vasan RS. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2007, 27:127-133. 10.1161/01.ATV.0000251993.20372.40, 17095717.
15. Meisinger C, Doring A, Schneider A, Lowel H. Serum gamma-glutamyltransferase is a predictor of incident coronary events in apparently healthy men from the general population. Atherosclerosis 2006, 189:297-302. 10.1016/j.atherosclerosis.2006.01.010, 16483579.
16. Ruttmann E, Brant LJ, Concin H, Diem G, Rapp K, Ulmer H. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation 2005, 112:2130-2137. 10.1161/CIRCULATIONAHA.105.552547, 16186419.
17. Wannamethee G, Ebrahim S, Shaper AG. Gamma-glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes. Am J Epidemiol 1995, 142:699-708.
18. Turgut O, Yilmaz A, Yalta K, Karadas F, Birhan Yilmaz M. gamma-Glutamyltransferase is a promising biomarker for cardiovascular risk. Medical hypotheses 2006, 67:1060-1064. 10.1016/j.mehy.2006.04.010, 16891060.
19. Fraser A, Harris R, Sattar N, Ebrahim S, Davey Smith G, Lawlor DA. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis. Diabetes Care 2009, 32:741-750. 10.2337/dc08-1870, 2660465, 19131466.
20. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44:865-873. 10.1002/hep.21327, 17006923.
21. Kain K, Carter AM, Grant PJ, Scott EM. Alanine aminotransferase is associated with atherothrombotic risk factors in a British South Asian population. J Thromb Haemost 2008, 6:737-741. 10.1111/j.1538-7836.2008.02935.x, 18315552.
22. Sattar N, Scherbakova O, Ford I, O'Reilly DS, Stanley A, Forrest E, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes 2004, 53:2855-2860. 10.2337/diabetes.53.11.2855, 15504965.
23. Steinvil A, Berliner S, Bromberg M, Cohen M, Shalev V, Shapira I, Rogowski O. Micro-inflammatory changes in asymptomatic healthy adults during bouts of respiratory tract infections in the community: potential triggers for atherothrombotic events. Atherosclerosis 2009, 206:270-275. 10.1016/j.atherosclerosis.2009.01.045, 19281986.
24. Rogowski O, Steinvil A, Berliner S, Cohen M, Saar N, Ben-Bassat OK, Shapira I. Elevated resting heart rate is associated with the metabolic syndrome. Cardiovasc Diabetol 2009, 8:55. 10.1186/1475-2840-8-55, 2768698, 19828043.
25. Rogowski O, Shapira I, Steinvil A, Berliner S. Low-grade inflammation in individuals with the hypertriglyceridemic waist phenotype: another feature of the atherogenic dysmetabolism. Metabolism 2009, 58:661-667. 10.1016/j.metabol.2009.01.005, 19375589.
26. Rogowski O, Shapira I, Peretz H, Berliner S. Glycohaemoglobin as a determinant of increased fibrinogen concentrations and low-grade inflammation in apparently healthy nondiabetic individuals. Clin Endocrinol (Oxf) 2008, 68:182-189.
27. Rogowski O, Shapira I, Shirom A, Melamed S, Toker S, Berliner S. Heart rate and microinflammation in men: a relevant atherothrombotic link. Heart 2007, 93:940-944. 10.1136/hrt.2006.101949, 17237129.
28. Rogowski O, Toker S, Shapira I, Melamed S, Shirom A, Zeltser D, Berliner S. Values of high-sensitivity C-reactive protein in each month of the year in apparently healthy individuals. Am J Cardiol 2005, 95:152-155. 10.1016/j.amjcard.2004.08.086, 15619418.
29. Steinvil A, Shirom A, Melamed S, Toker S, Justo D, Saar N, Shapira I, Berliner S, Rogowski O. Relation of educational level to inflammation-sensitive biomarker level. Am J Cardiol 2008, 102:1034-1039. 10.1016/j.amjcard.2008.05.055, 18929705.
30. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Jama 2001, 285:2486-2497. 10.1001/jama.285.19.2486, 11368702.
31. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645. 10.1161/CIRCULATIONAHA.109.192644, 19805654.
32. Barham D, Trinder P. An improved colour reagent for the determination of blood glucose by the oxidase system. Analyst 1972, 97:142-145. 10.1039/an9729700142, 5037807.
33. Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 1982, 28:2077-2080.
34. Izawa S, Okada M, Matsui H, Hotta Y, Hama H. A new direct method for measuring HDL-cholesterol which does not produce any biased values. Jpn J Med Pharm Sci 1997, 37:1385-1388.
35. Szasz G. Reaction-rate method for gamma-glutamyltransferase activity in serum. Clin Chem 1976, 22:2051-2055.
36. Bergmeyer HU, Horder M. International federation of clinical chemistry. Scientific committee. Expert panel on enzymes. IFCC document stage 2, draft 1; 1979-11-19 with a view to an IFCC recommendation. IFCC methods for the measurement of catalytic concentration of enzymes. Part 3. IFCC method for alanine aminotransferase. J Clin Chem Clin Biochem 1980, 18:521-534.
37. Kotronen A, Westerbacka J, Bergholm R, Pietilainen KH, Yki-Jarvinen H. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 2007, 92:3490-3497. 10.1210/jc.2007-0482, 17595248.
38. Paolicchi A, Emdin M, Passino C, Lorenzini E, Titta F, Marchi S, Malvaldi G, Pompella A. Beta-lipoprotein- and LDL-associated serum gamma-glutamyltransferase in patients with coronary atherosclerosis. Atherosclerosis 2006, 186:80-85. 10.1016/j.atherosclerosis.2005.07.012, 16112119.
39. Anderson ME, Allison RD, Meister A. Interconversion of leukotrienes catalyzed by purified gamma-glutamyl transpeptidase: concomitant formation of leukotriene D4 and gamma-glutamyl amino acids. Proc Natl Acad Sci USA 1982, 79:1088-1091. 10.1073/pnas.79.4.1088, 345905, 6122208.
40. Despres JP, Lemieux I, Bergeron J, Pibarot P, Mathieu P, Larose E, Rodes-Cabau J, Bertrand OF, Poirier P. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 2008, 28:1039-1049. 10.1161/ATVBAHA.107.159228, 18356555.
41. Tenenbaum A, Fisman EZ, Motro M. Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR). Cardiovascular diabetology 2003, 2:4. 10.1186/1475-2840-2-4, 153546, 12834541.
42. Patel DA, Srinivasan SR, Xu JH, Chen W, Berenson GS. Persistent elevation of liver function enzymes within the reference range is associated with increased cardiovascular risk in young adults: the Bogalusa Heart Study. Metabolism 2007, 56:792-798. 10.1016/j.metabol.2007.01.010, 17512312.